Neuropathic (nerve damage) pain affects up to 10% of the adult population. Currently available medications recommended for the treatment of neuropathic pain are often ineffective or they produce dose-limiting side-effects. Hence, neuropathic pain is an area of large unmet medical need. In this presentation, I will focus on the discovery and development of EMA401, a first-in-class novel analgesic agent that was initially commercialized by Spinifex Pharmaceuticals, a UQ spin-out company formed in mid-2005. A decade later after successful completion of a Phase 2a proof-of-concept clinical trial of EMA401 in patients with post-herpetic neuralgia, a type of neuropathic pain that is often intractable, Spinifex was acquired by Novartis in the largest biotech deal to date in Australia. Currently, EMA401 is in Phase 2b clinical trials by Novartis
Emeritus Prof Maree Smith is a leading researcher internationally in discovery/ translation with particular expertise in the novel pain therapeutics field. She is inventor on several patented novel analgesics technologies, with one licensed in 2005 to the UQ spin-out company, Spinifex Pharmaceuticals, for commercialization.
In mid-2015, Spinifex was acquired by Novartis and the drug candidate, EMA401, is in clinical development. Prof Smith also has expertise in deriving pharmacokinetic parameters from plasma drug concentration versus time data from animal and early phase human clinical trials. In the period, 2005-2017, whilst in the role of Executive Director, UQ Centre for Integrated Preclinical Drug Development (CIPDD), she led a high performing team to establish and grow the Centre and its industry engagement. In that period, Centre personnel undertook more than 700 contract-funded R&D studies in collaboration with >200 industry and academic collaborators in the biopharmaceutical sector.
Registrations close 5pm Friday 28 September 2018. Late registrations will not be accepted.
We understand that circumstances may change which have an effect on your ability to attend the event after it has been booked and paid for. Should your attendance plans change the following will apply:
Name change: A substitute delegate can be nominated to attend in your place at any time up to 24 hours prior to the start of the event. There is no fee for a change in delegate name up to this point. A name change within 24 hours of the start of the event will incur a 25 per cent administration fee.
Cancellation: Should you be unable to find a replacement and seek a refund, the following applies:
All name changes or cancellations must be advised in writing by email to firstname.lastname@example.org
View the Event Cancellation and Refund Policy.
To book tickets, please sign in with your username and password if you are not already logged in or use the "forgot my password or my username" links on the Sign In page to retrieve your details. If you have not previously registered for an event please create an account.
Promoting Australia's advancement through technology